Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3543-3548

  Goncalves A ^a   Braud, A C ^a   Viret, F ^a   Genre, D ^a   Gravis, G ^a   Tarpin, C ^a   Giovannini, M ^a   Maraninchi, D ^a,b   Viens, P ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Caelyx; Carboplatin; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ANUS CARCINOMA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEAD CANCER; HUMAN; KIDNEY CARCINOMA; MALE; MELANOMA; MUCOSA INFLAMMATION; NECK CANCER; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0041527176     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rahman A, Treat J, Roh JK, Potkul LA, Alvord WG, Forst D, and PV Woolley: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8: 1093-1100, 1990.
2. Gabizon AA, Barenholz Y and Bialer M: Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol- derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10: 703-708, 1993.
3. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K, Woodle MC, Lasic DD, Redemann C and Martin FJ: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11644, 1991.
4. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR and Dewhirst MW: Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53: 3765-3770, 1993.
5. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, and Jain RK: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54: 3352-3356, 1994.
6. Huang SK, Lee KD, Hong K, Friend DS and Papahadjopoulos D: Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52: 5135-5143, 1992.
7. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ and Papahadjopoulos D: Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52: 6774-6781, 1992.
8. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ and Bankert RB: Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 53: 3964-3967, 1993.
9. Siegal T, Horowitz A and Gabizon A: Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83: 1029-1037, 1995.
10. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S and Karkavitsas N: High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 83: 1281-1286, 2000.
11. Herman EH, Rahman A, Ferrans VJ, Vick JA and Schein PS: Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 43: 5427-5432, 1983.
12. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19: 424-436, 2001.
13. Stewart S, Jablonowski H, Goebel FI3 FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J and Dezube BJ: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin study Group. J Clin Oncol 16: 683-691, 1998.
14. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD and Henry DH: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J Clin Oncol 16: 2445-2451, 1998.
15. Perez AT, Domenech GH, Frankel C and Vogel CL: Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 20 (Suppl 2): 22-9, 2002.
16. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ and Liang LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15: 987-993, 1997.
17. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R and Sharpington T: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093-3100, 2000.
18. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322, 2001.
19. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM and Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777-1785, 1995.
20. Lebwohl D and Canetta R: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34: 1522-1534, 1998.
21. A'Hern RP and Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13: 726-732, 1995.
22. O'Quigley J, Pepe M and Fisher L: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46: 33-48, 1990.
23. Lyass O, Hubert A and Gabizon AA: Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 7: 3040-3046, 2001.
24. Klein P, Wasserheit C, Hochster H, Chachoua A, Speyer JL, Oratz R, Downey A, Sorich J, Kotcher L, Eisenberg T and Muggia F: Apparent protection of Doxil skin and oral toxicities when combined with cisplatin: results of a Phase I study. Proc Am Soc Clin Oncol 18: 217a, 1999.
25. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D and Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15: 3185-3191, 1997.